A carregar...
Genome-wide association study of cardiotoxicity in NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial
OBJECTIVES: The major clinical side-effect of the ERBB2 targeted breast cancer therapy, trastuzumab, is a decline in left ventricular ejection fraction (LVEF). Improved markers are needed to better identify patients susceptible to cardiotoxicity. METHODS: The NCCTG N9831 trial compared adjuvant doxo...
Na minha lista:
| Publicado no: | Pharmacogenet Genomics |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5581215/ https://ncbi.nlm.nih.gov/pubmed/28763429 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000302 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|